HC Wainwright Has Bullish Forecast for DNLI FY2028 Earnings
HC Wainwright raised their FY2028 earnings per share (EPS) estimates for Denali Therapeutics in a report issued on Tuesday, January 7th. HC Wainwright analyst A. Fein now expects that the company will ...
Denali Therapeutics (NASDAQ:DNLI) Earns Outperform Rating from Analysts at Robert W. Baird
Robert W. Baird assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a research note released on ...
Denali: Despite ALS Primary Endpoint Failure, Possible Path Forward Remains
Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click ...
Denali Therapeutics (NASDAQ:DNLI) Given New $24.00 Price Target at JPMorgan Chase & Co.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) had its target price decreased by stock analysts at JPMorgan Chase & Co. from $28.00 to $24.00 in a research report issued on Tuesday,Benzinga ...
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
Denali Therapeutics Inc. (NASDAQ: DNLI), today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for tividenofusp alfa (DNL310) for the treatment ...
Denali Therapeutics (NASDAQ:DNLI) Given New $87.00 Price Target at HC Wainwright
Denali Therapeutics (NASDAQ:DNLI – Free Report) had its price objective cut by HC Wainwright from $90.00 to $87.00 in a ...
Denali Therapeutics' Amyotrophic Lateral Sclerosis Misses Pivotal Trial, But Analyst Says It Was Expected
Denali Therapeutics Inc. (NASDAQ:DNLI) revealed topline results from an analysis of Regimen G of the Phase 2/3 HEALEY ALS ...
Biggest stock movers Tuesday: NARI, DNLI, and more
Stock futures were mixed in Tuesday’s premarket session as investors looked ahead to the release of the Job Openings and ...
Denali Therapeutics Inc. (NASDAQ:DNLI) Director Vicki L. Sato Sells 3,080 Shares of Stock
Director Vicki L. Sato sold 3,080 shares of the business’s stock in a transaction that occurred on Thursday, January 2nd. The ...
Denali Therapeutics Neurodegenerative Disease Platform Sparks Analyst Optimistic
William Blair has initiated coverage on Denali Therapeutics Inc (NASDAQ:DNLI), a company focused on developing drugs for ...
Nasdaq1mon
Why Is Denali Therapeutics (DNLI) Down 21.2% Since Last Earnings Report?
A month has gone by since the last earnings report for Denali Therapeutics Inc. (DNLI). Shares have lost about 21.2% in that time frame, underperforming the S&P 500. Will the recent negative trend ...
Nasdaq1mon
Stifel Upgrades Denali Therapeutics (DNLI)
Fintel reports that on December 16, 2024, Stifel upgraded their outlook for Denali Therapeutics (NasdaqGS:DNLI) from Hold to Buy. As of December 3, 2024, the average one-year price target for ...